Haoyang Peng
Datos Biográficos
| ID | 9999437 |
|---|---|
| NOMBRE | Haoyang Peng |
| NOMBRES | Haoyang |
| APELLIDO | Peng |
| FIRMA | PENG H |
| AFILIACIONES | Hebei Medical University |
| VERIFICADO | No |
| TOTAL DE OBRAS | 1 |
| TOTAL DE CITAS | 0 |
| OBRAS COMO AUTOR | 1 |
| OBRAS COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2026 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2026 |
| ÍNDICE H | 0 |
Cost–utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China
Background: Sacituzumab tirumotecan (Sac-TMT) has demonstrated survival benefits over chemotherapy in patients with previously treated metastatic triple-negative breast cancer (mTNBC). However, its economic value under different payment contexts in China remains uncertain. Methods: A state-transition (Markov) model was used to estimate lifetime costs and quality-adjusted life-years (QALYs) for Sac-TMT versus single-agent chemotherapy in second-li…
Sin obras prominentes en esta página.
Cost–utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China
Background: Sacituzumab tirumotecan (Sac-TMT) has demonstrated survival benefits over chemotherapy in patients with previously treated metastatic triple-negative breast cancer (mTNBC). However, its economic value under different payment contexts in China remains uncertain. Methods: A state-transition (Markov) model was used to estimate lifetime costs and quality-adjusted life-years (QALYs) for Sac-TMT versus single-agent chemotherapy in second-li…
Advanced Breast Cancer Therapies (1 obra) · Breast cancer (1 obra) · Breast Cancer Treatment Studies (1 obra) · Cancer Treatment and Pharmacology (1 obra) · China (1 obra) · List price (1 obra) · Metastatic breast cancer (1 obra) · Payment (1 obra) · Reimbursement (1 obra) · Willingness to pay (1 obra)